{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:35:58Z","timestamp":1755218158853,"version":"3.43.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The European Society for Medical Oncology (ESMO) 2021 Guidelines contraindicate the administration of chemotherapy in the last month of patients\u2019 life. The main objective of this multicenter observational retrospective study was to calculate the time elapsed between the date of the last chemotherapy and the date of death of patients with ovarian cancer. The secondary objectives were to identify any factors associated with a greater probability of receiving chemotherapy in the end of life.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Ovarian cancer patients operated between 2010 and 2020 in the participant Italian centers were enrolled. Only deceased patients whose date of death and date of last chemotherapy were known were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>603 women from 10 Italian centers were included. One patient out of four (25.7%) received chemotherapy in the last month of life. The median survival from the last chemotherapy was 66 days. Patients with a neutrophil\/lymphocyte ratio \u22655, with high C-reactive protein at the start of the last line and patients dying in hospital compared to hospice\/palliative care at home were more likely to undergo chemotherapy at the end of life (p&amp;lt;0.001, p=0.05 and p&amp;lt;0.001 respectively). Being treated in Northern Italy reduces the chance of receiving chemotherapy at the end of life in comparison with Center-South (p&amp;lt;0.001), as well as being enrolled in at least one clinical protocol (p=0.027).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The TO CARE\/MITO 42 study is a snapshot of the Italian practice in which there are still disparities in the treatment of patients at the end of life. A prospective observational study could provide useful elements for early identification of patients who would not benefit from a further line.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1641758","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T04:12:12Z","timestamp":1754453532000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Time tO last ChemotherApy and death in ovaRian cancEr patients: TO CARE\/MITO 42 study, a retrospective analysis of italian MITO centers"],"prefix":"10.3389","volume":"15","author":[{"given":"Giulia","family":"Scotto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Galat\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Fruscio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Besana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Landoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Sgro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Testi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fulvio","family":"Borella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennaro","family":"Cormio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariangela","family":"Gianciotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Arezzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigida Anna","family":"Maiorano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Baldoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marinella","family":"Destefanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jole","family":"Ventriglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Chiari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Carmen","family":"Azzolina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivano","family":"Raimondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Turinetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Tuninetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Valabrega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"B1","unstructured":"Estimates of cancer incidence and mortality in 2020, for all cancer sites\n          \n          2023"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"9951","journal-title":"Lancet (2014) Oct;"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds203","article-title":"The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy","volume":"23","author":"Hanker","year":"2012","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jpainsymman.2013.02.021","article-title":"Concepts and definitions for \u201cActively dying,\u201d \u201cEnd of life,\u201d \u201cTerminally ill,\u201d \u201cTerminal care,\u201d and \u201cTransition of care\u201d: a systematic review","volume":"47","author":"Hui","year":"2014","journal-title":"J Pain Symptom Manage"},{"key":"B6","doi-asserted-by":"publisher","first-page":"100225","DOI":"10.1016\/j.esmoop.2021.100225","article-title":"ESMO 2021 Care of the adult cancer patient at the end of life: ESMO Clinical Practice Guidelines ESMO Open","volume":"6","author":"Crawford","year":"2021","journal-title":"ESMO Open"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e0123764","DOI":"10.1371\/journal.pone.0123764","article-title":"Measuring intensity of end of life care: a systematic review","volume":"10","author":"Luta","year":"2015","journal-title":"PloS One"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102561","article-title":"Prevalence of aggressive care among patients with cancer near the end of life: a systematic review and meta-analysis","volume":"71","author":"Ma","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33488","article-title":"Trends and racial disparities in aggressive end of life care for a national sample of women with ovarian cancer","volume":"127","author":"Mullins","year":"2021","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.11.022","article-title":"The end of life costs for Medicare patients with advanced ovarian cancer","volume":"148","author":"Urban","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.5383","article-title":"End-of-life care for older patients with ovarian cancer is intensive despite high rates of hospice use","volume":"32","author":"Wright","year":"2014","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/10732748231157191","article-title":"Palliative medicine referral and end-of-life interventions among racial and ethnic minority patients with advanced or recurrent gynecologic cancer","volume":"30","author":"Tabuyo-Martin","year":"2023","journal-title":"Cancer Control"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.08.039","article-title":"Missed opportunities: patterns of medical care and hospice utilization among ovarian cancer patients","volume":"135","author":"Brown","year":"2014","journal-title":"Gynecol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.06.025","article-title":"The utilization of palliative care in gynecologic oncology patients near the end of life","volume":"127","author":"Fauci","year":"2012","journal-title":"Gynecol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-000338","article-title":"End-of-life symptoms and interventions among women with gynecologic cancers in a tertiary-care hospital in Thailand","volume":"29","author":"Sompratthana","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/jog.13219","article-title":"Clinical significance and predicting indicators of post-cancer-treatment survival in terminally ill patients with ovarian cancer","volume":"43","author":"Utsumi","year":"2017","journal-title":"J Obstet Gynaecol Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ygyno.2010.04.014","article-title":"End of life care for women with gynecologic cancers","volume":"118","author":"Barbera","year":"2010","journal-title":"Gynecol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.04.017","article-title":"End-of-life care for patients with advanced ovarian cancer in the Netherlands: A retrospective registry-based analysis","volume":"166","author":"Broekman","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1159\/000501721","article-title":"The EOLO (End-of-life ovarian cancer) study: approach to ovarian cancer patients at the end of life","volume":"97","author":"Palaia","year":"2019","journal-title":"Oncology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ygyno.2019.10.001","article-title":"Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(\u22653) chemotherapy - The GCIG symptom benefit study (SBS)","volume":"156","author":"Roncolato","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-021-06162-z","article-title":"Clinical indicators useful in decision-making about palliative chemotherapy for end-of-life ovarian cancer patients","volume":"305","author":"Kiuchi","year":"2022","journal-title":"Arch Gynecol Obstet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1861","article-title":"Determinants of patient-oncologist prognostic discordance in advanced cancer","volume":"2","author":"Gramling","year":"2016","journal-title":"JAMA Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12885-018-4318-5","article-title":"Prognostic value of systemic infammatory markers in ovarian Cancer: a PRISMA compliant meta-analysis and systematic review","volume":"18","author":"Zhu","year":"2018","journal-title":"BMC Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ygyno.2017.10.019","article-title":"Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC)\u2014analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS)","volume":"148","author":"Roncolato","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-002-0023-1","article-title":"The role of C-reactive protein as a prognostic indicator in advanced cancer","volume":"4","author":"Mahmoud","year":"2002","journal-title":"Curr Oncol Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1044","article-title":"Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer","volume":"14","author":"Hefler","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B27","unstructured":"National voluntary consensus standards for quality of cancer care, cancer care phase I-II, may 2009\n          \n          2021"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2013.0366","article-title":"Is there any association between where patients spend the end of life and survival after anticancer treatment for gynecologic Malignancy","volume":"17","author":"Kajiyama","year":"2014","journal-title":"J Palliat Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2019.0456","article-title":"Survival after anticancer treatment of terminally ill patients with ovarian carcinoma","volume":"23","author":"Kajiyama","year":"2020","journal-title":"J Palliat Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1017\/S1478951523000032","article-title":"End-of-life care for patients with cancer: Clinical, geographical, and sociocultural differences","volume":"22","author":"Ostan","year":"2023","journal-title":"Palliat Support Care"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-000851","article-title":"Clinical trial participation and aggressive care at the end of life in patients with ovarian cancer","volume":"30","author":"Nitecki","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2015.08.015","article-title":"Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC)","volume":"139","author":"Seifert","year":"2015","journal-title":"Gynecol Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1641758\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T04:12:15Z","timestamp":1754453535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1641758\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":32,"alternative-id":["10.3389\/fonc.2025.1641758"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1641758","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"article-number":"1641758"}}